Logotype for Charles River Laboratories International Inc

Charles River Laboratories (CRL) Q1 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Charles River Laboratories International Inc

Q1 2025 earnings summary

9 Jul, 2026

Executive summary

  • Q1 2025 revenue was $984.2 million, down 2.7% year-over-year, but organic revenue fell only 1.8%, outperforming expectations due to strong DSA segment results and improved bookings.

  • Non-GAAP EPS rose 3.1% to $2.34, while GAAP EPS dropped to $0.50, reflecting restructuring and one-time charges; net income available to common shareholders was $25.5 million, down from $67.3 million.

  • Cost-saving initiatives and restructuring drove non-GAAP operating margin up 60 bps to 19.1%, while GAAP margin fell to 7.6% due to lower revenue and accelerated amortization.

  • $350 million in stock repurchases were completed in Q1 2025, with $549.3 million remaining authorized.

  • Strategic review and board refresh launched with Elliott Investment Management to unlock value.

Financial highlights

  • Service revenue declined 2.3% to $797.9 million; product revenue fell 4.3% to $186.2 million year-over-year.

  • Non-GAAP operating margin rose to 19.1% (up 60 bps); GAAP margin dropped to 7.6% (down 490 bps); free cash flow was $112.4 million, more than doubling year-over-year.

  • Capital expenditures were $59.3 million, down from $79.1 million year-over-year.

  • Cash and cash equivalents at quarter-end were $229.4 million; debt at $2.5 billion, with 60% fixed rate.

  • Gross leverage ratio was 2.5x; net leverage 2.4x; interest coverage ratio 6.23x.

Outlook and guidance

  • 2025 organic revenue guidance improved to a 4.5% to 2.5% decline; non-GAAP EPS guidance raised to $9.30–$9.80; GAAP EPS guidance is $4.30–$4.85.

  • DSA organic revenue expected to decline mid-single digits, improved from prior outlook; RMS outlook moderated to flat to slightly positive growth.

  • Manufacturing revenue expected to be flat organically for 2025; margin expected to rebound as volumes improve.

  • Q2 revenue expected to decline low to mid-single digits year-over-year, with sequential EPS improvement.

  • Management targets $225 million in annualized cost savings from restructuring, with $175 million impacting 2025.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more